eXoZymes Inc. (EXOZ) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While EXOZ currently carries a cautious 36/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.68) and Max Pain ($4.32) forces dealer call-delta covering toward $19.32.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
eXoZymes Inc. (EXOZ) dropped -2.72% to $4.11, trading at 6% of its 52-week range ($3.24 – $18.4). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
* October 22 investor event will explore ' commercialization, manufacturing economics, path to market launch, growth strategy, and milestones ahead.LOS ANGELES, CA / ACCESS Newswire / October 21, 2026 / Today, Inc.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on EXOZ today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for EXOZ. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, eXoZymes Inc. (EXOZ) ranks #792 by composite RQD confidence (36/100, grade D-) and #780 by equity capitalization ($38.2M). Within this direct 5-issuer industry benchmark cohort, EXOZ leads on earnings valuation at N/A trailing P/E, while EXOZ leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. INMB currently holds the highest overall quantitative score in the immediate peer group at 45/100 (D) compared with EXOZ at 36/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| EXOZ
ACTIVE
eXoZymes Inc. | D- | 36/100 | — | — | -35.0% | -2.72% | $38.2M | Benchmark Subject |
| ELUT Elutia Inc. (Class A) | E | 34/100 | — | 53.7% | -35.0% | -3.13% | $36.0M | /elut-vs-exoz → |
| INMB INmune Bio Inc. | D | 45/100 | — | — | -35.0% | +4.58% | $44.4M | /inmb-vs-exoz → |
| IMA ImageneBio Inc. | E | 24/100 | — | — | -35.0% | -3.57% | $46.0M | /ima-vs-exoz → |
| ESLA Estrella Immunopharma Inc. | D- | 41/100 | — | — | -35.0% | -11.32% | $31.7M | /esla-vs-exoz → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), eXoZymes Inc. (EXOZ) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 , and -100.0% cumulative change since FY2023) , GAAP net income of -$9.2M, operating cash flow of -$6.5M, and free cash flow of -$6.7M (+25.1% YoY). On the balance sheet, EXOZ closed FY2025 with $6.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$9.2M | -$6.5M | -$6.7M | $6.0M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$5.9M | -$8.5M | -$8.9M | $13.0M | — |
| FY2023 (FY) | 2023-12-31 | $70.1K | -$2.0M | -$1.2M | -$1.2M | — | — |
As of 2026-11-01, eXoZymes Inc. (NASDAQ: EXOZ) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $4.11 (-2.72% 1D, market cap $38.2M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, EXOZ ranks #792 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), EXOZ carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ELUT (Elutia Inc. (Class A)) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $36.0M) and INMB (INmune Bio Inc.) posts a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $44.4M). Among the 5-stock peer group, EXOZ leads on earnings multiple (N/A) while EXOZ leads on capital efficiency (-35.0% ROIC).
Per EXOZ's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002010788), eXoZymes Inc. generated $0 in revenue, -$9.2M in net income, and -$6.7M in free cash flow against $6.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
EXOZ last traded at $4.11 (-2.72% on volume of 9,234 shares), positioning the stock -27.64% below its 50-day simple moving average ($5.68) and -47.10% below its 200-day simple moving average ($7.77). Across its 52-week range of $3.24 to $18.40, EXOZ sits at the 5.7% percentile with a 14-day RSI of 36.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.60 to $4.62).
Why EXOZ Stock dropped -2.72% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.